Abstract
Oxazolidinones make up a relatively new class of antimicrobial agents which possess a unique mechanism of bacterial protein synthesis inhibition. U-100592 (S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]- phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide and U-100766 (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]- 2-oxo-5-oxazolidinyl]methyl]-acetamide are novel oxazolidinone analogs from a directed chemical modification program. MICs were determined for a variety of bacterial clinical isolates; the respective MICs of U-100592 and U-100766 at which 90% of isolates are inhibited were as follows: methicillin-susceptible Staphylococcus aureus, 4 and 4 micrograms/ml; methicillin-resistant S. aureus, 4 and 4 micrograms/ml; methicillin-susceptible Staphylococcus epidermidis, 2 and 2 micrograms/ml; methicillin-resistant S. epidermidis, 1 and 2 micrograms/ml; Enterococcus faecalis, 2 and 4 micrograms/ml; Enterococcus faecium, 2 and 4 micrograms/ml; Streptococcus pyogenes, 1 and 2 micrograms/ml; Streptococcus pneumoniae, 0.50 and 1 microgram/ml; Corynebacterium spp., 0.50 and 0.50 micrograms/ml; Moraxella catarrhalis, 4 and 4 micrograms/ml; Listeria monocytogenes, 8 and 2 micrograms/ml; and Bacteroides fragilis, 16 and 4 micrograms/ml. Most strains of Mycobacterium tuberculosis and the gram-positive anaerobes were inhibited in the range of 0.50 to 2 micrograms/ml. Enterococcal strains resistant to vancomycin (VanA, VanB, and VanC resistance phenotypes), pneumococcal strains resistant to penicillin, and M. tuberculosis strains resistant to common antitubercular agents (isoniazid, streptomycin, rifampin, ethionamide, and ethambutol) were not cross-resistant to the oxazolidinones. The presence of 10, 20, and 40% pooled human serum did not affect the antibacterial activities of the oxazolidinones. Time-kill studies demonstrated a bacteriostatic effect of the analogs against staphylococci and enterococci but a bactericidal effect against streptococci. The spontaneous mutation frequencies of S. aureus ATCC 29213 were <3.8 x 10(-10) and <8 x 10(-11) for U-100592 and U-100766, respectively. Serial transfer of three staphylococcal and two enterococcal strains on drug gradient plates produced no evidence of rapid resistance development. Thus, these new oxazolidinone analogs demonstrated in vitro antibacterial activities against a variety of clinically important human pathogens.
Full Text
The Full Text of this article is available as a PDF (232.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Ashtekar D. R., Costa-Periera R., Shrinivasan T., Iyyer R., Vishvanathan N., Rittel W. Oxazolidinones, a new class of synthetic antituberculosis agent. In vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis. Diagn Microbiol Infect Dis. 1991 Nov-Dec;14(6):465–471. doi: 10.1016/0732-8893(91)90002-w. [DOI] [PubMed] [Google Scholar]
- Barry A. L. In vitro evaluation of DuP 105 and DuP 721, two new oxazolidinone antimicrobial agents. Antimicrob Agents Chemother. 1988 Jan;32(1):150–152. doi: 10.1128/aac.32.1.150. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Brumfitt W., Hamilton-Miller J. M. In-vitro microbiological activities of DuP 105 and DuP 721, novel synthetic oxazolidinones. J Antimicrob Chemother. 1988 Jun;21(6):711–720. doi: 10.1093/jac/21.6.711. [DOI] [PubMed] [Google Scholar]
- Daly J. S., Eliopoulos G. M., Reiszner E., Moellering R. C., Jr Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds. J Antimicrob Chemother. 1988 Jun;21(6):721–730. doi: 10.1093/jac/21.6.721. [DOI] [PubMed] [Google Scholar]
- Daly J. S., Eliopoulos G. M., Willey S., Moellering R. C., Jr Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound. Antimicrob Agents Chemother. 1988 Sep;32(9):1341–1346. doi: 10.1128/aac.32.9.1341. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Eustice D. C., Feldman P. A., Slee A. M. The mechanism of action of DuP 721, a new antibacterial agent: effects on macromolecular synthesis. Biochem Biophys Res Commun. 1988 Feb 15;150(3):965–971. doi: 10.1016/0006-291x(88)90723-1. [DOI] [PubMed] [Google Scholar]
- Eustice D. C., Feldman P. A., Zajac I., Slee A. M. Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis. Antimicrob Agents Chemother. 1988 Aug;32(8):1218–1222. doi: 10.1128/aac.32.8.1218. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Krogstad D. J., Pargwette A. R. Defective killing of enterococci: a common property of antimicrobial agents acting on the cell wall. Antimicrob Agents Chemother. 1980 Jun;17(6):965–968. doi: 10.1128/aac.17.6.965. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mini E., Novelli A., Mazzei T., Periti P. Comparative in vitro activity of the new oxazolidinones DuP 721 and DuP 105 against staphylococci and streptococci. Eur J Clin Microbiol Infect Dis. 1989 Mar;8(3):256–260. doi: 10.1007/BF01965273. [DOI] [PubMed] [Google Scholar]
- Neu H. C., Novelli A., Saha G., Chin N. X. In vitro activities of two oxazolidinone antimicrobial agents, DuP 721 and DuP 105. Antimicrob Agents Chemother. 1988 Apr;32(4):580–583. doi: 10.1128/aac.32.4.580. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Slee A. M., Wuonola M. A., McRipley R. J., Zajac I., Zawada M. J., Bartholomew P. T., Gregory W. A., Forbes M. Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721. Antimicrob Agents Chemother. 1987 Nov;31(11):1791–1797. doi: 10.1128/aac.31.11.1791. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Stratton C. W., Liu C., Ratner H. B., Weeks L. S. Bactericidal activity of deptomycin (LY146032) compared with those of ciprofloxacin, vancomycin, and ampicillin against enterococci as determined by kill-kinetic studies. Antimicrob Agents Chemother. 1987 Jul;31(7):1014–1016. doi: 10.1128/aac.31.7.1014. [DOI] [PMC free article] [PubMed] [Google Scholar]